Data is what drives cancer research forward, providing novel insights that enable the creation of life-saving diagnostic tools and therapies. Through our extensive partnerships and specialized bioinformatics services, M2GEN is revolutionizing the way oncology data is collected and analyzed, making the future of cancer research brighter than ever.
M2GEN leverages the power of data collected through the Oncology Research Information Exchange Network® (ORIEN), an alliance of the nation’s top cancer centers. The unique Total Cancer Care® (TCC) protocol powers the ORIEN network’s operations, allowing for the collection of longitudinal clinical and molecular data over the lifetime of consenting patients who agree to be re-contacted. To date, more than 300,000 patients have enrolled, making it one of the most comprehensive registries in the world. By eliminating the barriers between patients, physicians, and researchers, these partnerships serve as a powerful engine, generating a robust cache of raw data on many different cancer types in a wide array of patient cohorts.
Aligning with the ORIEN Mission of accelerating cancer discovery and delivering hope through collaborative learning and partnerships, ORIEN Intermember Projects encourage research opportunities between ORIEN member institutions, and are inclusive of nonmember and industry partners. ORIEN Intermember Projects provide a forum for clinical and scientific experts to exchange ideas and identify areas for collaboration to address unmet needs; advancing cancer research and patient care.
ORIEN Members are currently collaborating on on over 40 Intermember Projects providing a forum for clinical and scientific experts to address unmet needs; advancing cancer research and patient care. Learn more about this research by visiting the ORIEN website.
Using the Total Cancer Care® Protocol as a master trial-screening protocol, M2GEN was able to dramatically accelerate enrollment for an otherwise challenging biomarker-driven clinical trial in gastric and pancreatic cancers. M2GEN is collaborating with leading biopharmaceutical companies in the development of “synthetic control arms.” One such example is a Phase 2 CAR-T clinical trial. Enrollment of patients in the TCC protocol offers patients increased probability of being matched to effective clinical trial. Additionally, the pace of clinical trial development can be accelerated by taking a proactive approach to rapidly identify eligible patients for the trial using the ORIEN Avatar data. This approach improves clinical trial efficiency by reducing study timeline and overall costs. Centrally managed by M2GEN, the ORIEN Clinical Trials Network (OCTN) provides the ability to identify patients for target-based clinical trials. In addition to the rapid patient identification process, OCTN further enhances trial efficiency through a centralized protocol review and approval process.
Our ecosystem is scientifically rooted and believes meaningful advancements for patients come from data-driven decisions. See how we are already contributing to the fight against cancer. The following publications were developed by ORIEN Members based on Total Cancer Care data.
DACH1 mutation frequency in endometrial cancer is associated with high tumor mutation burden. Riggs MJ, Lin N, Wang C, Piecoro DW, Miller RW, Hampton OA, et al. (2020) PLoS ONE 15(12): e0244558. https://doi.org/10.1371/journal.pone.0244558
Recommendations for patient similarity classes: results of the AMIA 2019 workshop on defining patient similarity. Seligson ND, Warner JL, Dalton WS, et al. [published online ahead of print, 2020 Sep 4]. J Am Med Inform Assoc. 2020;ocaa159. doi:10.1093/jamia/ocaa159
Genomic and immunologic correlates of LAG-3 expression in cancer. Panda A, Rosenfeld JA, Singer EA, Bhanot G & Ganesan S (2020), OncoImmunology, 9:1, DOI:10.1080/2162402X.2020.1756116
Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease.
Mason, M.J., Schinke, C., Eng, C.L.P. et al. Leukemia (2020). https://doi.org/10.1038/s41375-020-0742-z
Transcriptionally Active Androgen Receptor Splice Variants Promote Hepatocellular Carcinoma Progression.
Dauki AM, Blachly JS, Kautto EA, Ezzat S, Abdel-Rahman MH, Coss CC. Cancer Res. 2020 Feb 1;80(3):561-575. doi:10.1158/0008-5472.CAN-19-1117. Epub 2019 Nov 4. PubMed PMID: 31685543; PubMed Central PMCID: PMC7002251.
Effects of Tobacco Smoking on the Tumor Immune Microenvironment in Head and Neck Squamous Cell Carcinoma.
de la Iglesia JV, Slebos RJC, Martin-Gomez L, Wang X, Teer JK, Tan AC, Gerke TA, Aden-Buie G, van Veen T, Masannat J, Chaudhary R, Song F, Fournier M, Siegel EM, Schabath MB, Wadsworth JT, Caudell J, Harrison L, Wenig BM, Conejo-Garcia J, Hernandez-Prera JC, Chung CH. Clin Cancer Res. 2020 Mar 15;26(6):1474-1485. doi: 10.1158/1078-0432.CCR-19-1769. Epub 2019 Dec 17. PubMed PMID: 31848186; PubMed Central PMCID: PMC7073297.
Yun S, Sharma R, Chan O, Vincelette ND, Sallman DA, Sweet K, Padron E, Komrokji R, Lancet JE, Abraham I, Moscinski LC, Cleveland JL, List AF, Zhang L. Leuk Res. 2019 Sep;84:106194. doi: 10.1016/j.leukres.2019.106194. Epub 2019 Jul 18. PubMed PMID: 31357093. https://www.ncbi.nlm.nih.gov/pubmed/31357093
Stewart PA, Welsh EA, Slebos RJC, Fang B, Izumi V, Chambers M, Zhang G, Cen L, Pettersson F, Zhang Y, Chen Z, Cheng CH, Thapa R, Thompson Z, Fellows KM, Francis JM, Saller JJ, Mesa T, Zhang C, Yoder S, DeNicola GM, Beg AA, Boyle TA, Teer JK, Ann Chen Y, Koomen JM, Eschrich SA, Haura EB. Nat Commun. 2019 Aug 8;10(1):3578. doi:10.1038/s41467-019-11452-x. PubMed PMID: 31395880; PubMed Central PMCID: PMC6687710. https://www.ncbi.nlm.nih.gov/pubmed/31395880
Mirza AS, Yun S, Ali NA, Shin H, O'Neil JL, Elharake M, Schwartz D, Robinson K, Nowell E, Engle G, Badat I, Brimer T, Kuc A, Sequeira A, Mirza S, Sikaria D, Vera JD, Hackney N, Abusrur S, Jesurajan J, Kuang J, Patel S, Khalil S, Bhaskar S, Beard A, Abuelenen T, Ratnasamy K, Visweshwar N, Komrokji R, Jaglal M. Thromb J. 2019 Jul 2;17:13. doi: 1186/s12959-019-0202-z. eCollection 2019. PubMed PMID: 31303864; PubMed Central PMCID: PMC6604148. https://www.ncbi.nlm.nih.gov/pubmed/31303864
Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Lu Y, Beeghly-Fadiel A, Wu L, Guo X, Li B, Schildkraut JM, Im HK, Chen YA, Permuth JB, Reid BM, Teer JK, Moysich KB, Andrulis IL, Anton-Culver H, Arun BK, Bandera EV, Barkardottir RB, Barnes DR, Benitez J, Bjorge L, Brenton J, Butzow R, Caldes T, Caligo MA, Campbell I, Chang-Claude J, Claes KBM, Couch FJ, Cramer DW, Daly MB, deFazio A, Dennis J, Diez O, Domchek SM, Dörk T, Easton DF, Eccles DM, Fasching PA, Fortner RT, Fountzilas G, Friedman E, Ganz PA, Garber J, Giles GG, Godwin AK, Goldgar DE, Goodman MT, Greene MH, Gronwald J, Hamann U, Heitz F, Hildebrandt MAT, Høgdall CK, Hollestelle A, Hulick PJ, Huntsman DG, Imyanitov EN, Isaacs C, Jakubowska A, James P, Karlan BY, Kelemen LE, Kiemeney LA, Kjaer SK, Kwong A, Le ND, Leslie G, Lesueur F, Levine DA, Mattiello A, May T, McGuffog L, McNeish IA, Merritt MA, Modugno F, Montagna M, Neuhausen SL, Nevanlinna H, Nielsen FC, Nikitina-Zake L, Nussbaum RL, Offit K, Olah E, Olopade OI, Olson SH, Olsson H, Osorio A, Park SK, Parsons MT, Peeters PHM, Pejovic T, Peterlongo P, Phelan CM, Pujana MA, Ramus SJ, Rennert G, Risch H, Rodriguez GC, Rodríguez-Antona C, Romieu I, Rookus MA, Rossing MA, Rzepecka IK, Sandler DP, Schmutzler RK, Setiawan VW, Sharma P, Sieh W, Simard J, Singer CF, Song H, Southey MC, Spurdle AB, Sutphen R, Swerdlow AJ, Teixeira MR, Teo SH, Thomassen M, Tischkowitz M, Toland AE, Trichopoulou A, Tung N, Tworoger SS, van Rensburg EJ, Vanderstichele A, Vega A, Edwards DV, Webb PM, Weitzel JN, Wentzensen N, White E, Wolk A, Wu AH, Yannoukakos D, Zorn KK, Gayther SA, Antoniou AC, Berchuck A, Goode EL, Chenevix-Trench G, Sellers TA, Pharoah PDP, Zheng W, Long J. A Cancer Res. 2018 Sep 15;78(18):5419-5430. doi: 10.1158/0008-5472.CAN-18-0951. Epub 2018 Jul 27. PubMed PMID: 30054336; PubMed Central PMCID: PMC6139053. https://www.ncbi.nlm.nih.gov/pubmed/30054336
Quantification of Breast Cancer Protein Biomarkers at Different Expression Levels in Human Tumors. Chen Y, Britton D, Wood ER, Brantley S, Fournier M, Wloch M, Williams VL, Johnson J, Magliocco A, Pike I, Koomen JM. Methods Mol Biol. 2018;1788:251-268. doi: 10.1007/7651_2017_113. PubMed PMID: 29243084.
Circulating T Cell Subpopulations Correlate With Immune Responses at the Tumor Site and Clinical Response to PD1 Inhibition in Non-Small Cell Lung Cancer. Manjarrez-Orduño N, Menard LC, Kansal S, Fischer P, Kakrecha B, Jiang C, Cunningham M, Greenawalt D, Patel V, Yang M, Golhar R, Carman JA, Lezhnin S, Dai H, Kayne PS, Suchard SJ, Bernstein SH, Nadler SG. Front Immunol. 2018 Aug 3;9:1613. doi: 10.3389/fimmu.2018.01613. eCollection 2018. PubMed PMID: 30123214; PubMed Central PMCID: PMC6085412.